Evaluation

end (open chromatin), Cristiano cohort cross-validation

Published comparison; transcribed, not reproduced.

Research readiness

These checks assess whether the evidence supports a reproducible investigation. A source-checked score alone does not meet these requirements.

Release 2026-10-10-7b8f80935f90 · Evidence verified: Not verified

Evidence incomplete

Replay metrics

Exact outcomes, predictions, identifiers and evaluator are connected.

Missing or unresolved evidence

No verified artifact manifest is linked to this exact record.
artifact hashes: verification is missing
join integrity: verification is missing
score semantics: verification is missing
metric replay: verification is missing

Verified: Not verified

Evidence incomplete

Investigate discrepancies

Replay evidence includes annotations and an assessment of dependence. Unknown independence permits descriptive analysis only.

Missing or unresolved evidence

No verified artifact manifest is linked to this exact record.
artifact hashes: verification is missing
join integrity: verification is missing
score semantics: verification is missing
metric replay: verification is missing
annotations: verification is missing
dependence: verification is missing

Verified: Not verified

Evidence incomplete

Run locally

A pinned recipe describes the inputs, environment and resource requirements.

Missing or unresolved evidence

No verified artifact manifest is linked to this exact record.
artifact hashes: verification is missing
join integrity: verification is missing
score semantics: verification is missing
recipe pinned: verification is missing
resource estimate: verification is missing

Verified: Not verified

Evidence incomplete

Validate independently

Separate data and exposure records support an independent test.

Missing or unresolved evidence

No verified artifact manifest is linked to this exact record.
artifact hashes: verification is missing
join integrity: verification is missing
score semantics: verification is missing
independent validation: verification is missing
overlap checked: verification is missing

Verified: Not verified

Readiness describes the evidence in this release. Availability on your computer is checked separately when an investigation runs. Existing data exposure can prevent independent validation even when files are available.

Artifacts and reproduction

No verified artifact manifest is connected to this record yet. The gaps above identify what is needed before analysis can begin.

Read reviewed discrepancy investigations

Evaluation results

1 evaluation · 22 results. Different protocols are not a single leaderboard.

Filter evaluations

Tested model or methodProtocolDatasetEvaluation setupMetricEvidence origin

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configuration	Protocol and dataset	Finding	Evidence and details
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.974 auroc unitless · higher Uncertainty: 95% CI 0.9641 to 0.9834 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C18; group 'BRCA'; row 'end'; column 'AUC'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.941 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.9220 to 0.9600 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E18; group 'BRCA'; row 'end'; column 'Sensitivity @85% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.862 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.8305 to 0.8942 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D18; group 'BRCA'; row 'end'; column 'Sensitivity @95% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.969 auroc unitless · higher Uncertainty: 95% CI 0.9596 to 0.9788 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C28; group 'CHOL'; row 'end'; column 'AUC'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.853 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.8055 to 0.9012 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E28; group 'CHOL'; row 'end'; column 'Sensitivity @85% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.75 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.6867 to 0.8133 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D28; group 'CHOL'; row 'end'; column 'Sensitivity @95% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.975 auroc unitless · higher Uncertainty: 95% CI 0.9665 to 0.9837 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C38; group 'CRC'; row 'end'; column 'AUC'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.885 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.8432 to 0.9268 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E38; group 'CRC'; row 'end'; column 'Sensitivity @85% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.843 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.7956 to 0.8911 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D38; group 'CRC'; row 'end'; column 'Sensitivity @95% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.999 auroc unitless · higher Uncertainty: 95% CI 0.9971 to 1.0000 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C58; group 'NSCLC'; row 'end'; column 'AUC'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	1 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 1.0000 to 1.0000 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E58; group 'NSCLC'; row 'end'; column 'Sensitivity @85% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.97 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.9366 to 1.0000 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D58; group 'NSCLC'; row 'end'; column 'Sensitivity @95% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.999 auroc unitless · higher Uncertainty: 95% CI 0.9978 to 0.9997 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C68; group 'OV'; row 'end'; column 'AUC'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	1 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 1.0000 to 1.0000 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E68; group 'OV'; row 'end'; column 'Sensitivity @85% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.973 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.9533 to 0.9933 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D68; group 'OV'; row 'end'; column 'Sensitivity @95% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.837 auroc unitless · higher Uncertainty: 95% CI 0.8058 to 0.8680 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C78; group 'PAAD'; row 'end'; column 'AUC'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.717 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.6658 to 0.7675 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E78; group 'PAAD'; row 'end'; column 'Sensitivity @85% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.598 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.5398 to 0.6568 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D78; group 'PAAD'; row 'end'; column 'Sensitivity @95% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.964 auroc unitless · higher Uncertainty: 95% CI 0.9586 to 0.9692 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C8; group 'PANCAN'; row 'end'; column 'AUC'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.963 auroc unitless · higher Uncertainty: 95% CI 0.9442 to 0.9810 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C48; group 'STAD'; row 'end'; column 'AUC'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.927 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.8959 to 0.9574 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E48; group 'STAD'; row 'end'; column 'Sensitivity @85% specificity'
Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.87 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.8285 to 0.9115 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source end (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D48; group 'STAD'; row 'end'; column 'Sensitivity @95% specificity'

Source checking is not independent reproduction. Release 2026-10-10-7b8f80935f90.

Evaluation procedure

ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024)
Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort

origin: Independent external evaluation
configuration: Primary source as retrieved 2026-10-09
protocol id: ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity
dataset version: Cristiano et al. 2019 cohort, fragment files from FinaleDB
split: 10 repeats of 10-fold cross-validation
population: Pan-cancer (208) and each of seven cancer types vs 215 healthy individuals
inputs: end features in open chromatin regions
adaptation: SVM trained per fold and per comparison
metric implementation: Not reported
aggregation: Mean with 95% CI
budget: Not reported

Metadata review: source checked. Unreported conditions prevent automatic comparisons.

Reproduction

Split: 10 repeats of 10-fold cross-validation
Adaptation: SVM trained per fold and per comparison
Scoring implementation: Not reported

No execution recipe has been verified for this exact configuration and evaluation. A benchmark's general instructions may use different inputs, splits or model settings.

Reproducing this published result requires matching its model configuration, data, split and scorer. Source checking or a successful smoke test does not establish score reproduction.

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

36 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-10-10-7b8f80935f90
Property and statement	Original source and location	Review and provenance
attributes.comparison.adaptation SVM trained per fold and per comparison Context-only references	Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns Original source ↗ Supporting Information Table S2, row 'end' in each of groups PANCAN to PAAD Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML Retrieved: 2026-10-09T20:27:02Z	not individually reviewed No individual claim review recorded independent paper Audit details Field: `attributes.comparison.adaptation` Source artifact SHA-256: `d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
attributes.comparison.adaptation SVM trained per fold and per comparison Context-only references	Hou et al. 2024, Supporting Information workbook (Tables S1-S15) Original source ↗ Supporting Information Table S2, row 'end' in each of groups PANCAN to PAAD Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: ADVS-11-2308243-s001.xlsx, PMC open-access copy PMC11321639.1 Retrieved: 2026-10-09T20:20:39Z	not individually reviewed No individual claim review recorded independent paper Audit details Field: `attributes.comparison.adaptation` Source artifact SHA-256: `41b24f7e6bcb9bea6127a249127a4c4d53e8ea42b50e95242054791511695fb0` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
attributes.comparison.aggregation Mean with 95% CI Context-only references	Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns Original source ↗ Supporting Information Table S2, row 'end' in each of groups PANCAN to PAAD Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML Retrieved: 2026-10-09T20:27:02Z	not individually reviewed No individual claim review recorded independent paper Audit details Field: `attributes.comparison.aggregation` Source artifact SHA-256: `d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
attributes.comparison.aggregation Mean with 95% CI Context-only references	Hou et al. 2024, Supporting Information workbook (Tables S1-S15) Original source ↗ Supporting Information Table S2, row 'end' in each of groups PANCAN to PAAD Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: ADVS-11-2308243-s001.xlsx, PMC open-access copy PMC11321639.1 Retrieved: 2026-10-09T20:20:39Z	not individually reviewed No individual claim review recorded independent paper Audit details Field: `attributes.comparison.aggregation` Source artifact SHA-256: `41b24f7e6bcb9bea6127a249127a4c4d53e8ea42b50e95242054791511695fb0` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
attributes.comparison.budget Not reported Context-only references	Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns Original source ↗ Supporting Information Table S2, row 'end' in each of groups PANCAN to PAAD Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML Retrieved: 2026-10-09T20:27:02Z	missing or unspecified No individual claim review recorded independent paper Audit details Field: `attributes.comparison.budget` Source artifact SHA-256: `d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
attributes.comparison.budget Not reported Context-only references	Hou et al. 2024, Supporting Information workbook (Tables S1-S15) Original source ↗ Supporting Information Table S2, row 'end' in each of groups PANCAN to PAAD Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: ADVS-11-2308243-s001.xlsx, PMC open-access copy PMC11321639.1 Retrieved: 2026-10-09T20:20:39Z	missing or unspecified No individual claim review recorded independent paper Audit details Field: `attributes.comparison.budget` Source artifact SHA-256: `41b24f7e6bcb9bea6127a249127a4c4d53e8ea42b50e95242054791511695fb0` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
attributes.comparison.dataset_version Cristiano et al. 2019 cohort, fragment files from FinaleDB Context-only references	Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns Original source ↗ Supporting Information Table S2, row 'end' in each of groups PANCAN to PAAD Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML Retrieved: 2026-10-09T20:27:02Z	not individually reviewed No individual claim review recorded independent paper Audit details Field: `attributes.comparison.dataset_version` Source artifact SHA-256: `d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
attributes.comparison.dataset_version Cristiano et al. 2019 cohort, fragment files from FinaleDB Context-only references	Hou et al. 2024, Supporting Information workbook (Tables S1-S15) Original source ↗ Supporting Information Table S2, row 'end' in each of groups PANCAN to PAAD Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: ADVS-11-2308243-s001.xlsx, PMC open-access copy PMC11321639.1 Retrieved: 2026-10-09T20:20:39Z	not individually reviewed No individual claim review recorded independent paper Audit details Field: `attributes.comparison.dataset_version` Source artifact SHA-256: `41b24f7e6bcb9bea6127a249127a4c4d53e8ea42b50e95242054791511695fb0` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
attributes.comparison.inputs end features in open chromatin regions Context-only references	Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns Original source ↗ Supporting Information Table S2, row 'end' in each of groups PANCAN to PAAD Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML Retrieved: 2026-10-09T20:27:02Z	not individually reviewed No individual claim review recorded independent paper Audit details Field: `attributes.comparison.inputs` Source artifact SHA-256: `d029fc9d593a70fc350fa86cf1c6393ab5121479396b448ea2c0cdd87b6ace70` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact
attributes.comparison.inputs end features in open chromatin regions Context-only references	Hou et al. 2024, Supporting Information workbook (Tables S1-S15) Original source ↗ Supporting Information Table S2, row 'end' in each of groups PANCAN to PAAD Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: ADVS-11-2308243-s001.xlsx, PMC open-access copy PMC11321639.1 Retrieved: 2026-10-09T20:20:39Z	not individually reviewed No individual claim review recorded independent paper Audit details Field: `attributes.comparison.inputs` Source artifact SHA-256: `41b24f7e6bcb9bea6127a249127a4c4d53e8ea42b50e95242054791511695fb0` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact

All evidence (JSONL) (gzip)How to read the evidence

Sources and history

Release 2026-10-10-7b8f80935f90 · Record review: source checked

2 source records and release history

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns · Original source · Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML
Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Original source · ADVS-11-2308243-s001.xlsx, PMC open-access copy PMC11321639.1

Download this release (gzip)

Technical metadata and extraction receipts

Stable ID: ctdnafrag-20261009-eval-hou2024-s2-fragment-end-count-cristiano

areas: dna-genomes
contexts: clinical_research
origin: independent_paper
protocol: ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity
version: Primary source as retrieved 2026-10-09
comparison: protocol id: ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity; dataset version: Cristiano et al. 2019 cohort, fragment files from FinaleDB; split: 10 repeats of 10-fold cross-validation; population: Pan-cancer (208) and each of seven cancer types vs 215 healthy individuals; inputs: end features in open chromatin regions; adaptation: SVM trained per fold and per comparison; metric implementation: Not reported; aggregation: Mean with 95% CI; budget: Not reported
source locator: Supporting Information Table S2, row 'end' in each of groups PANCAN to PAAD
missing metadata: comparison.metric implementation: reason: unreported

Related records

Suggest a correction